IMCD NV (IMCD)
Euronext Amsterdam · Netherlands · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 100.55 |
|---|---|
| 52-week range | 68.14 – 105.55 |
| Return, 1 month / 3 months | +5.6% / +12.6% |
| Return, 1 year / 3 years | +8.0% / −4.4% |
| Trend | Uptrend |
| RSI (14) | 55 |
| Volatility (1 year) | 35.5% |
| Worst drawdown (1 year) | -26.4% |
| Average daily value traded | 12.80M EUR |
| Dividend yield | 1.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
IMCD is a distributor of specialty chemicals and ingredients based in the Netherlands. The company buys these products from producers and supplies them, along with technical advice and formulation support, to manufacturers and formulators. Its customers operate in industries such as pharmaceuticals, food and nutrition, personal care, coatings, plastics and industrial applications. IMCD works through a network of local offices and application laboratories, helping suppliers reach smaller and specialised customers while giving buyers access to a broad range of ingredients.
The shares are listed on the Euronext Amsterdam in Netherlands under the code IMCD, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
IMCD NV (IMCD) trades on the Euronext Amsterdam in Netherlands. It last closed at EUR 100.55 on 22 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 32 of 109 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 8.0% and over the last three months it rose 12.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Amsterdam
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 83 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 13.0% | ||
| From 52-week high | -4.0% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 12.6% | ||
| 6-month return | 6.2% | ||
| 12-month return, skipping the last month | 2.2% | ||
| Stability (higher is calmer) | 44 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 35.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.4% | ||
| Liquidity | 74 · Strong | Trades actively. | |
| Average daily value traded | 12.80M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 34 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.8% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −2.7% |
|---|---|
| 1 month | +5.6% |
| 3 months | +12.6% |
| 6 months | +6.2% |
| 1 year | +8.0% |
| 3 years | −4.4% |
| 5 years | −42.0% |
Signals
| 50-day / 200-day average | 97.71 / 88.98 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.20 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 May 2026 | EUR 1.8100 |
| 29 Apr 2025 | EUR 2.1500 |
| 16 May 2024 | EUR 2.2400 |
| 2 May 2023 | EUR 2.3700 |
| 4 May 2022 | EUR 1.6200 |
| 24 Jun 2021 | EUR 1.0200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Amsterdam; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.